1) Buy some precious time for thousands of CFers by stabilizing or improving lung function,
2) Increase media focus on curing CF,
3) Keep fundraising momentum going, and
4) Maintain hope within the CF community about future advancements.
|Sorry this one is blurry! |
It shows that a 3 drug combo restored about 58% CFTR function in the lab.
In the near future, we will also hear more about the VX-661/VX-770 combination. In some ways, VX-661 is known to be a superior corrector compound to VX-809. VX-809 is not highly compatible with VX-770 (The presence of VX-809 degrades the action of VX-770. To get an effective dosage of VX-770, they had to pump up the initial dosage to 250 mg.--100 mg. more than the standard dosage for Kalydeco monotherapy. Anytime you increase drug dosages, you run the risk of increased problems with metabolism by liver and kidneys, or other side effects). VX-661 does not have this type of interaction with VX-770, and just seems to work better in general. This two drug combo would still be considered "first generation," but could at least represent an option for some folks sooner than a second generation combo.